Ketamine, a clinically used anesthetic, inhibits vascular smooth muscle cell proliferation via PP2A-activated PI3K/Akt/ERK inhibition

Yi Chang, Jiun Yi Li, Thanasekaran Jayakumar, Shou Huang Hung, Wei Cheng Lee, Manjunath Manubolu, Joen Rong Sheu, Ming Jen Hsu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Abnormal proliferation of vascular smooth muscle cells (VSMCs) gives rise to major pathological processes involved in the development of cardiovascular diseases. The use of anti-proliferative agents for VSMCs offers potential for the treatment of vascular disorders. Intravenous anesthetics are firmly established to have direct effects on VSMCs, resulting in modulation of blood pressure. Ketamine has been used for many years in the intensive care unit (ICU) for sedation, and has recently been considered for adjunctive therapy. In the present study, we investigated the effects of ketamine on platelet-derived growth factor BB (PDGF-BB)-induced VSMC proliferation and the associated mechanism. Ketamine concentration-dependently inhibited PDGF-BB-induced VSMC proliferation without cytotoxicity, and phosphatidylinositol 3-kinase (PI3K) and extracellular signal-regulated protein kinase (ERK) inhibitors, LY294002 and PD98059, respectively, have similar inhibitory effects. Ketamine was shown to attenuate PI3K, Akt, and ERK1/2 phosphorylation induced by PDGF-BB. Okadaic acid, a selective protein phosphatase 2A (PP2A) inhibitor, significantly reversed ketamine-mediated PDGF-BB-induced PI3K, Akt, and ERK1/2 phosphorylation; a transfected protein phosphatse 2a (pp2a) siRNA reversed Akt and ERK1/2 phosphorylation; and 3-O-Methyl-sphingomyeline (3-OME), an inhibitor of sphingomyelinase, also significantly reversed ERK1/2 phosphorylation. Moreover, ketamine alone significantly inhibited tyrosine phosphorylation and demethylation of PP2A in a concentration-dependent manner. In addition, the pp2a siRNA potently reversed the ketamine-activated catalytic subunit (PP2A-C) of PP2A. These results provide evidence of an anti-proliferating effect of ketamine in VSMCs, showing activation of PP2A blocks PI3K, Akt, and ERK phosphorylation that subsequently inhibits the proliferation of VSMCs. Thus, ketamine may be considered a potential effective therapeutic agent for reducing atherosclerotic process by blocking the proliferation of VSMCs.

Original languageEnglish
Article number2545
JournalInternational Journal of Molecular Sciences
Volume18
Issue number12
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Phosphatidylinositol 3-Kinase
anesthetics
Enzyme inhibition
smooth muscle
Protein Phosphatase 2
muscle cells
Anesthetics
phosphatases
Phosphatases
Cell proliferation
Ketamine
Vascular Smooth Muscle
phosphorylation
Phosphorylation
Smooth Muscle Myocytes
Muscle
Cell Proliferation
proteins
Proteins
Platelets

Keywords

  • Akt
  • ERK1/2
  • Ketamine
  • PDGF-BB
  • PP2A
  • Pp2a siRNA
  • VSMC

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Ketamine, a clinically used anesthetic, inhibits vascular smooth muscle cell proliferation via PP2A-activated PI3K/Akt/ERK inhibition. / Chang, Yi; Li, Jiun Yi; Jayakumar, Thanasekaran; Hung, Shou Huang; Lee, Wei Cheng; Manubolu, Manjunath; Sheu, Joen Rong; Hsu, Ming Jen.

In: International Journal of Molecular Sciences, Vol. 18, No. 12, 2545, 01.12.2017.

Research output: Contribution to journalArticle

Chang, Yi ; Li, Jiun Yi ; Jayakumar, Thanasekaran ; Hung, Shou Huang ; Lee, Wei Cheng ; Manubolu, Manjunath ; Sheu, Joen Rong ; Hsu, Ming Jen. / Ketamine, a clinically used anesthetic, inhibits vascular smooth muscle cell proliferation via PP2A-activated PI3K/Akt/ERK inhibition. In: International Journal of Molecular Sciences. 2017 ; Vol. 18, No. 12.
@article{2e76ef83d9174bf1bc1a41248a8a9db1,
title = "Ketamine, a clinically used anesthetic, inhibits vascular smooth muscle cell proliferation via PP2A-activated PI3K/Akt/ERK inhibition",
abstract = "Abnormal proliferation of vascular smooth muscle cells (VSMCs) gives rise to major pathological processes involved in the development of cardiovascular diseases. The use of anti-proliferative agents for VSMCs offers potential for the treatment of vascular disorders. Intravenous anesthetics are firmly established to have direct effects on VSMCs, resulting in modulation of blood pressure. Ketamine has been used for many years in the intensive care unit (ICU) for sedation, and has recently been considered for adjunctive therapy. In the present study, we investigated the effects of ketamine on platelet-derived growth factor BB (PDGF-BB)-induced VSMC proliferation and the associated mechanism. Ketamine concentration-dependently inhibited PDGF-BB-induced VSMC proliferation without cytotoxicity, and phosphatidylinositol 3-kinase (PI3K) and extracellular signal-regulated protein kinase (ERK) inhibitors, LY294002 and PD98059, respectively, have similar inhibitory effects. Ketamine was shown to attenuate PI3K, Akt, and ERK1/2 phosphorylation induced by PDGF-BB. Okadaic acid, a selective protein phosphatase 2A (PP2A) inhibitor, significantly reversed ketamine-mediated PDGF-BB-induced PI3K, Akt, and ERK1/2 phosphorylation; a transfected protein phosphatse 2a (pp2a) siRNA reversed Akt and ERK1/2 phosphorylation; and 3-O-Methyl-sphingomyeline (3-OME), an inhibitor of sphingomyelinase, also significantly reversed ERK1/2 phosphorylation. Moreover, ketamine alone significantly inhibited tyrosine phosphorylation and demethylation of PP2A in a concentration-dependent manner. In addition, the pp2a siRNA potently reversed the ketamine-activated catalytic subunit (PP2A-C) of PP2A. These results provide evidence of an anti-proliferating effect of ketamine in VSMCs, showing activation of PP2A blocks PI3K, Akt, and ERK phosphorylation that subsequently inhibits the proliferation of VSMCs. Thus, ketamine may be considered a potential effective therapeutic agent for reducing atherosclerotic process by blocking the proliferation of VSMCs.",
keywords = "Akt, ERK1/2, Ketamine, PDGF-BB, PP2A, Pp2a siRNA, VSMC",
author = "Yi Chang and Li, {Jiun Yi} and Thanasekaran Jayakumar and Hung, {Shou Huang} and Lee, {Wei Cheng} and Manjunath Manubolu and Sheu, {Joen Rong} and Hsu, {Ming Jen}",
year = "2017",
month = "12",
day = "1",
doi = "10.3390/ijms18122545",
language = "English",
volume = "18",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "12",

}

TY - JOUR

T1 - Ketamine, a clinically used anesthetic, inhibits vascular smooth muscle cell proliferation via PP2A-activated PI3K/Akt/ERK inhibition

AU - Chang, Yi

AU - Li, Jiun Yi

AU - Jayakumar, Thanasekaran

AU - Hung, Shou Huang

AU - Lee, Wei Cheng

AU - Manubolu, Manjunath

AU - Sheu, Joen Rong

AU - Hsu, Ming Jen

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Abnormal proliferation of vascular smooth muscle cells (VSMCs) gives rise to major pathological processes involved in the development of cardiovascular diseases. The use of anti-proliferative agents for VSMCs offers potential for the treatment of vascular disorders. Intravenous anesthetics are firmly established to have direct effects on VSMCs, resulting in modulation of blood pressure. Ketamine has been used for many years in the intensive care unit (ICU) for sedation, and has recently been considered for adjunctive therapy. In the present study, we investigated the effects of ketamine on platelet-derived growth factor BB (PDGF-BB)-induced VSMC proliferation and the associated mechanism. Ketamine concentration-dependently inhibited PDGF-BB-induced VSMC proliferation without cytotoxicity, and phosphatidylinositol 3-kinase (PI3K) and extracellular signal-regulated protein kinase (ERK) inhibitors, LY294002 and PD98059, respectively, have similar inhibitory effects. Ketamine was shown to attenuate PI3K, Akt, and ERK1/2 phosphorylation induced by PDGF-BB. Okadaic acid, a selective protein phosphatase 2A (PP2A) inhibitor, significantly reversed ketamine-mediated PDGF-BB-induced PI3K, Akt, and ERK1/2 phosphorylation; a transfected protein phosphatse 2a (pp2a) siRNA reversed Akt and ERK1/2 phosphorylation; and 3-O-Methyl-sphingomyeline (3-OME), an inhibitor of sphingomyelinase, also significantly reversed ERK1/2 phosphorylation. Moreover, ketamine alone significantly inhibited tyrosine phosphorylation and demethylation of PP2A in a concentration-dependent manner. In addition, the pp2a siRNA potently reversed the ketamine-activated catalytic subunit (PP2A-C) of PP2A. These results provide evidence of an anti-proliferating effect of ketamine in VSMCs, showing activation of PP2A blocks PI3K, Akt, and ERK phosphorylation that subsequently inhibits the proliferation of VSMCs. Thus, ketamine may be considered a potential effective therapeutic agent for reducing atherosclerotic process by blocking the proliferation of VSMCs.

AB - Abnormal proliferation of vascular smooth muscle cells (VSMCs) gives rise to major pathological processes involved in the development of cardiovascular diseases. The use of anti-proliferative agents for VSMCs offers potential for the treatment of vascular disorders. Intravenous anesthetics are firmly established to have direct effects on VSMCs, resulting in modulation of blood pressure. Ketamine has been used for many years in the intensive care unit (ICU) for sedation, and has recently been considered for adjunctive therapy. In the present study, we investigated the effects of ketamine on platelet-derived growth factor BB (PDGF-BB)-induced VSMC proliferation and the associated mechanism. Ketamine concentration-dependently inhibited PDGF-BB-induced VSMC proliferation without cytotoxicity, and phosphatidylinositol 3-kinase (PI3K) and extracellular signal-regulated protein kinase (ERK) inhibitors, LY294002 and PD98059, respectively, have similar inhibitory effects. Ketamine was shown to attenuate PI3K, Akt, and ERK1/2 phosphorylation induced by PDGF-BB. Okadaic acid, a selective protein phosphatase 2A (PP2A) inhibitor, significantly reversed ketamine-mediated PDGF-BB-induced PI3K, Akt, and ERK1/2 phosphorylation; a transfected protein phosphatse 2a (pp2a) siRNA reversed Akt and ERK1/2 phosphorylation; and 3-O-Methyl-sphingomyeline (3-OME), an inhibitor of sphingomyelinase, also significantly reversed ERK1/2 phosphorylation. Moreover, ketamine alone significantly inhibited tyrosine phosphorylation and demethylation of PP2A in a concentration-dependent manner. In addition, the pp2a siRNA potently reversed the ketamine-activated catalytic subunit (PP2A-C) of PP2A. These results provide evidence of an anti-proliferating effect of ketamine in VSMCs, showing activation of PP2A blocks PI3K, Akt, and ERK phosphorylation that subsequently inhibits the proliferation of VSMCs. Thus, ketamine may be considered a potential effective therapeutic agent for reducing atherosclerotic process by blocking the proliferation of VSMCs.

KW - Akt

KW - ERK1/2

KW - Ketamine

KW - PDGF-BB

KW - PP2A

KW - Pp2a siRNA

KW - VSMC

UR - http://www.scopus.com/inward/record.url?scp=85035786467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035786467&partnerID=8YFLogxK

U2 - 10.3390/ijms18122545

DO - 10.3390/ijms18122545

M3 - Article

AN - SCOPUS:85035786467

VL - 18

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 12

M1 - 2545

ER -